The topical application of ophthalmic drugs is most commonly in the form of aqueous drops. These have the disadvantage of a short corneal contact time, resulting in only a small amount of the drug passing into the eye. The majority is quickly removed via the nasolacrimal duct, with subsequent systemic absorption.
proxymetacaine drops (175 ,ug). Corneal touch sensitivity was measured before, and at 1, 2, 5, 10, 15, 20, 30, 45, and 60 minutes following instillation. Complete anaesthesia was achieved in the majority of subjects within 1 minute ofinstillation. The lowest NODS dose (44 pg) produced longer lasting anaesthesia than the 35 VI drop (175 rig) (p<005). Higher NODS doses produced a correspondingly greater increase in the duration of anaesthesia. The greater bioavailability achieved by this vehicle allows much lower drug concentrations to be used, reducing the likelihood of systemic adverse reactions. (BrJ Ophthalmol 1993; 77: [713] [714] [715] The topical application of ophthalmic drugs is most commonly in the form of aqueous drops. These have the disadvantage of a short corneal contact time, resulting in only a small amount of the drug passing into the eye. The majority is quickly removed via the nasolacrimal duct, with subsequent systemic absorption.
A novel ophthalmic drug delivery system (NODS, Smith and Nephew Pharmaceuticals Ltd) has been developed' whch delivers a precise amount of drug to the eye. The drug is incorporated into a soluble polyvinyl alcohol (PVA) flag. This is attached to a water soluble handle film via a thin soluble membrane (Fig 1) . Subjects and methods Subjects consisted of 28 men with a mean age of 25-3 (SD 3 9) years. These were recruited from a university undergraduate population and included: 16 (57dI%) whites, 10 (35 7%) Asians, one (3 6%) black African, and one (3-6%) oriental. They had no history of ocular pathology, and none of the subjects were contact lens wearers. A screening examination excluded any corneal pathology.
Two versions of the Cochet-Bonnet aesthesiometer were used to measure the touch sensitivity of a paracentral corneal location. One aesthesiometer incorporated a 008 mm diameter nylon monofilament, covering a range of 2-90 mg/ 011005 mm', and the other a 0412 mm filament diameter with a range of 11-145 mg/O10113 mm'. The aesthesiometer was attached to a slit-lamp biomicroscope using a mount which allows precise control of filament orientation.56 The filament tip, held in constant focus through the Corneal integrity was checked using the slit- lamp biomicroscope at the end of each session, and at a follow up appointment the next day.
Statistical analysis
In analysing the data the proportion of subjects achieving total anaesthesia for each NODS was compared with the proportion for the eyedrop (positive control) at each time point using McNemar's test.
Results
For the purpose of this study total anaesthesia was assumed when there was no subjective touch sensitivity to a 1 cm length of the 0-12 mm diameter filament. For each preparation the onset of anaesthesia was extremely rapid. This was followed by a variable interval of maximal anaesthesia, with a gradual restoration of full sensitivity (Fig 2) . In three out of a total of 84 separate NODS instillations complete anaesthesia was not achieved, and there was a rapid return to baseline sensitivity. These anomalies were included in the statistical analysis, and account for the fact that full anaesthesia was not achieved by 100% of subjects for both the 44 [tg and 124 ig NODS (Fig 2) .
The results of the statistical analysis are summarised in Table 1 tions to be used. To achieve an equivalent duration of anaesthesia to the standard eyedrop a still lower NODS dose than the minimum used in the present study would be required. However, should more prolonged anaesthesia be necessary then the NODS vehicle could be used to produce extended periods of anaesthesia from a single instillation.
With three NODS units complete anaesthesia was not achieved. The most likely explanation is that the PVA membrane was blinked out of the conjunctival sac soon after instillation. This is strengthened by the observation, in one individual, of the incompletely dissolved membrane on the lower eyelid margin. It is therefore important to be aware of this possibility when using NODS.
Although NODS would reduce the likelihood of a systemic adverse reaction, it is possible that by maintaining a higher tear film concentration of the drug the vehicle could increase the risk of an ocular adverse response. Although few ocular or systemic reactions to proxymetacaine have been reported7 subclinical reactions have been shown to occur. A significant increase in corneal epithelial cell sloughing occurs for 6 hours after a single instillation of 05% proxymetacaine drops,8 and morphological changes in corneal epithelial cells were observed after using the drug in ointment form.9
In conclusion, NODS is an effective vehicle for proxymetacaine. The vehicle has several advantages over the available eye drop formulations. It is a preservative free, single dose system which has been demonstrated to give improved bioavailability. However, NODS may possibly increase the risk of an ocular adverse reaction.
